دورية أكاديمية
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
| العنوان: | Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) |
|---|---|
| المؤلفون: | Faivre-Finn, Corinne, Spigel, David R, Senan, Suresh, Langer, Corey, Perez, Bradford A, Özgüroğlu, Mustafa, Daniel, Davey, Villegas, Augusto, Vicente, David, Hui, Rina, Murakami, Shuji, Paz-Ares, Luis, Broadhurst, Helen, Wadsworth, Catherine, Dennis, Phillip A, Antonia, Scott J |
| المصدر: | Faivre-Finn , C , Spigel , D R , Senan , S , Langer , C , Perez , B A , Özgüroğlu , M , Daniel , D , Villegas , A , Vicente , D , Hui , R , Murakami , S , Paz-Ares , L , Broadhurst , H , Wadsworth , C , Dennis , P A & Antonia , S J 2021 , ' Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) ' , Lung Cancer , vol. 151 , pp. 30-38 . https://doi.org/10.1016/j.lungcan.2020.11.024Test |
| سنة النشر: | 2021 |
| الوصف: | Introduction: The PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC and stable or responding disease following concurrent, platinum-based chemoradiotherapy (CRT). A range of CT and RT regimens were permitted, and used, in the trial. We report post-hoc, exploratory analyses of clinical outcomes from PACIFIC according to CRT-related variables. Methods: Patients were randomized 2:1 (1–42 days post-CRT) to up to 12 months durvalumab (10 mg/kg intravenously every 2 weeks) or placebo. Efficacy and safety were analyzed in patient subgroups defined by the following baseline variables: platinum-based CT (cisplatin/carboplatin); vinorelbine, etoposide, or taxane-based CT (all yes/no); total RT dose (<60 Gy/60–66 Gy/>66 Gy); time from last RT dose to randomization (<14 days/≥14 days); and use of pre-CRT induction CT (yes/no). Treatment effects for time-to-event endpoints were estimated by hazard ratios (HRs) from unstratified Cox-proportional-hazards models. Results: Overall, 713 patients were randomized, of whom 709 received treatment in either the durvalumab (n/N = 473/476) or placebo arms (n/N = 236/237). Durvalumab improved PFS, versus placebo, across all subgroups (median follow up, 14.5 months; HR range, 0.34–0.63). Durvalumab improved OS across most subgroups (median follow up, 25.2 months; HR range, 0.35–0.86); however, the 95 % confidence interval (CI) of the estimated treatment effect crossed one for the subgroups of patients who received induction CT (HR, 0.78 [95 % CI, 0.51–1.20]); carboplatin (0.86 [0.60–1.23]); vinorelbine (0.79 [0.49–1.27]); and taxane-based CT (0.73 [0.51–1.04]); and patients who were randomized ≥14 days post-RT (0.81 [0.62–1.06]). Safety was broadly similar across the CRT subgroups. Conclusion: Durvalumab prolonged PFS and OS irrespective of treatment variables related to prior CRT to which patients with Stage III NSCLC had previously stabilized or responded. Limited ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://research.vumc.nl/en/publications/a94e824c-5543-4cff-95c7-1dd8269a3f90Test |
| DOI: | 10.1016/j.lungcan.2020.11.024 |
| الإتاحة: | https://doi.org/10.1016/j.lungcan.2020.11.024Test https://research.vumc.nl/en/publications/a94e824c-5543-4cff-95c7-1dd8269a3f90Test http://www.scopus.com/inward/record.url?scp=85097251886&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D520424C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.lungcan.2020.11.024 |
|---|